Abstract

Uzbekistan inherited a hospital-based health system from the Soviet Union. We explore the health system-related challenges faced during the scale-up of ambulatory (outpatient) treatment for drug-susceptible and drug-resistant tuberculosis (TB) in Karakalpakstan in Uzbekistan. Semi-structured interviews were conducted with key informants of the TB services, the ministries of health and finance, and their TB control partners. Structural challenges and resource needs were both discussed as obstacles to the expansion of ambulatory TB treatment. Respondents stated need for revising the financing mechanisms of the TB services to incentivize referral to ambulatory TB treatment. An increased workload and need for transportation in ambulatory TB care were also pointed out by respondents, given the quickly rising outpatient numbers but per capita financing of outpatient care. Policy makers showed strong interest in good practice examples for financing ambulatory-based management of TB in comparable contexts and in guidance for revising the financing of the TB services in a way that strengthens ambulatory TB treatment. To facilitate changing the model of care, TB control strategies emphasizing ambulatory care in hospital-oriented health systems should anticipate health system support and strengthening needs, and provide a plan of action to resolve both. Addressing both types of needs may require not only involving TB control and health financing actors, but also increasing knowledge about viable and tested financing mechanisms that incentivize the adoption of new models of care for TB.

Highlights

  • Ambulatory-based management of tuberculosis (TB), including multidrug-resistant tuberculosis (MDR-TB), appears to be effective and cost-effective in a variety of settings [1,2,3,4,5,6]

  • This exploratory qualitative study was implemented aiming to assess the policy for allocation of funds for TB care in Karakalpakstan, the ways in which it undermines the implementation of decentralized ambulatory care, and how the health financing could be changed to support the expansion of ambulatory care for drug-susceptible and drug-resistant TB

  • Interview content that related to the financing of ambulatory TB care and its expansion was stratified into three main themes: health system strengthening, health system support and resources available

Read more

Summary

Introduction

Ambulatory-based management of tuberculosis (TB), including multidrug-resistant tuberculosis (MDR-TB), appears to be effective and cost-effective in a variety of settings [1,2,3,4,5,6]. For the WHO European Region, a new TB action plan was adopted in September 2015 It states that all WHO high-priority countries for TB control in the European region should specify strategies and mechanisms for expanding and maintaining ambulatory TB treatment by 2016 [17]. The hospitalization level of MDR-TB patients (at least for part of the treatment) was between 75 and 100 % in Eastern European countries, with the lowest levels in Central Asia (30–40 % in Kazakhstan, Tajikistan and Uzbekistan). Many more TB patients could and, based on the preliminary evidence on effectiveness and cost-effectiveness of ambulatory MDR-TB treatment [2,3,4,5,6], probably should be treated using ambulatory-based care rather than hospital-based care in several high MDR-TB burden countries. Neither fiscal nor other forms of incentives are traditionally used for the regulation of health care providers [19, 34]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call